RU2019138177A - Производные 2-аминохинолина - Google Patents
Производные 2-аминохинолина Download PDFInfo
- Publication number
- RU2019138177A RU2019138177A RU2019138177A RU2019138177A RU2019138177A RU 2019138177 A RU2019138177 A RU 2019138177A RU 2019138177 A RU2019138177 A RU 2019138177A RU 2019138177 A RU2019138177 A RU 2019138177A RU 2019138177 A RU2019138177 A RU 2019138177A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- salt
- quinolin
- ethoxymethyl
- imidazo
- Prior art date
Links
- 150000005013 2-aminoquinolines Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 51
- 150000001875 compounds Chemical class 0.000 claims 30
- -1 4 - ((4-amino-2-ethoxy-methyl-1-methyl-1H-imidazo [4,5-c] quinolin-9-yl) oxy) -2-methylbutan-2-ol Chemical class 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 4
- HSEMFIZWXHQJAE-UHFFFAOYSA-N hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(N)=O HSEMFIZWXHQJAE-UHFFFAOYSA-N 0.000 claims 4
- VOZORYRGGNVPJW-UHFFFAOYSA-N 10-oxa-4,14-diazatricyclo[7.5.1.05,15]pentadeca-1(15),2,4,6,8,11,13-heptaen-12-ol Chemical compound N1=CC=C2C=3C(=CC=CC1=3)OC=C(C=N2)O VOZORYRGGNVPJW-UHFFFAOYSA-N 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- GKFPOIUULJGQPN-UHFFFAOYSA-N 1-[4-amino-2-(2-hydroxyethyl)-9-methoxyimidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2CC(C)(O)C)CCO)OC GKFPOIUULJGQPN-UHFFFAOYSA-N 0.000 claims 1
- WZRGIGQHNDGFIG-UHFFFAOYSA-N 1-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxy-2-methylpropan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2C)COCC)OCC(C)(O)C WZRGIGQHNDGFIG-UHFFFAOYSA-N 0.000 claims 1
- QOYVKJKPMJGWOA-UHFFFAOYSA-N 1-[4-amino-2-(ethoxymethyl)-9-methoxyimidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2CC(C)(O)C)COCC)OC QOYVKJKPMJGWOA-UHFFFAOYSA-N 0.000 claims 1
- YHYFYUKNKQMNOK-UHFFFAOYSA-N 1-[4-amino-9-methoxy-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2CC(C)(O)C)CCOC)OC YHYFYUKNKQMNOK-UHFFFAOYSA-N 0.000 claims 1
- BLYHFWNPCIGTHH-UHFFFAOYSA-N 1-[[4-amino-2-(ethoxymethyl)-3H-imidazo[4,5-c]quinolin-9-yl]oxy]propan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2)COCC)OCC(C)O BLYHFWNPCIGTHH-UHFFFAOYSA-N 0.000 claims 1
- CPAODTBRTBTGDI-UHFFFAOYSA-N 10-oxa-4,14-diazatricyclo[7.5.1.05,15]pentadeca-1(15),2,4,6,8,13-hexaen-12-one Chemical compound N1=CC=C2C=3C(=CC=CC1=3)OCC(C=N2)=O CPAODTBRTBTGDI-UHFFFAOYSA-N 0.000 claims 1
- UEFOMEYNTZNHQB-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-(2-methylpropoxy)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OCC(C)C)N)N=1)C UEFOMEYNTZNHQB-UHFFFAOYSA-N 0.000 claims 1
- HJNCPVOAGHSHPK-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-(2-morpholin-4-ylethoxy)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OCCN2CCOCC2)N)N=1)C HJNCPVOAGHSHPK-UHFFFAOYSA-N 0.000 claims 1
- XDTSMYJPPAAGLU-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-(2-propan-2-yloxyethoxy)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OCCOC(C)C)N)N=1)C XDTSMYJPPAAGLU-UHFFFAOYSA-N 0.000 claims 1
- AZTFHSKKWCHQKW-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-(oxolan-3-yloxy)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC2COCC2)N)N=1)C AZTFHSKKWCHQKW-UHFFFAOYSA-N 0.000 claims 1
- IXJQFWNIWIELNR-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-piperidin-4-yloxyimidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC2CCNCC2)N)N=1)C IXJQFWNIWIELNR-UHFFFAOYSA-N 0.000 claims 1
- UIVUUEFCKIJLNB-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-propan-2-yloxyimidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC(C)C)N)N=1)C UIVUUEFCKIJLNB-UHFFFAOYSA-N 0.000 claims 1
- WAFQYUYNGVIVNG-UHFFFAOYSA-N 2-(ethoxymethyl)-1-methyl-9-pyrrolidin-3-yloxyimidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC2CNCC2)N)N=1)C WAFQYUYNGVIVNG-UHFFFAOYSA-N 0.000 claims 1
- XKMXEEZJOCABSN-UHFFFAOYSA-N 2-(ethoxymethyl)-9-(2-methylpropoxy)-3H-imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1NC2=C(C(=NC=3C=CC=C(C2=3)OCC(C)C)N)N=1 XKMXEEZJOCABSN-UHFFFAOYSA-N 0.000 claims 1
- HRWIFFDHQMFGNN-UHFFFAOYSA-N 2-(ethoxymethyl)-9-(2-propan-2-yloxyethoxy)-3H-imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1NC2=C(C(=NC=3C=CC=C(C2=3)OCCOC(C)C)N)N=1 HRWIFFDHQMFGNN-UHFFFAOYSA-N 0.000 claims 1
- YGDTZZRKAQEXFO-UHFFFAOYSA-N 2-(ethoxymethyl)-9-(3-methylbutoxy)-3H-imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1NC2=C(C(=NC=3C=CC=C(C2=3)OCCC(C)C)N)N=1 YGDTZZRKAQEXFO-UHFFFAOYSA-N 0.000 claims 1
- PLKWRVIXFITHLR-UHFFFAOYSA-N 2-(ethoxymethyl)-9-methoxy-1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC)N)N=1)CC(C)C PLKWRVIXFITHLR-UHFFFAOYSA-N 0.000 claims 1
- VUJGOQDZTMOKFV-UHFFFAOYSA-N 2-(ethoxymethyl)-9-methoxy-1-(2-propan-2-yloxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical class C(C)OCC=1N(C2=C(C(=NC=3C=CC=C(C2=3)OC)N)N=1)CCOC(C)C VUJGOQDZTMOKFV-UHFFFAOYSA-N 0.000 claims 1
- KEXGXOJEMYADSG-UHFFFAOYSA-N 2-butyl-9-(3-methylbutoxy)pyrazolo[3,4-c]quinolin-4-amine Chemical class C(CCC)N1N=C2C(=NC=3C=CC=C(C=3C2=C1)OCCC(C)C)N KEXGXOJEMYADSG-UHFFFAOYSA-N 0.000 claims 1
- FLKJVZNZWBSCNA-UHFFFAOYSA-N 4-[4-amino-2-(ethoxymethyl)-1-(2-methylpropyl)imidazo[4,5-c]quinolin-9-yl]oxy-2-methylbutan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2CC(C)C)COCC)OCCC(C)(O)C FLKJVZNZWBSCNA-UHFFFAOYSA-N 0.000 claims 1
- OCIADYZDROIKDL-UHFFFAOYSA-N 4-[4-amino-2-(ethoxymethyl)-9-methoxyimidazo[4,5-c]quinolin-1-yl]-2-methylbutan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2CCC(C)(O)C)COCC)OC OCIADYZDROIKDL-UHFFFAOYSA-N 0.000 claims 1
- ITPHJKRCXVELDB-UHFFFAOYSA-N 4-[[4-amino-2-(2-methoxyethyl)-3H-imidazo[4,5-c]quinolin-9-yl]oxy]-2-methylbutan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2)CCOC)OCCC(C)(O)C ITPHJKRCXVELDB-UHFFFAOYSA-N 0.000 claims 1
- REWHSGXVPGPMCX-UHFFFAOYSA-N 4-[[4-amino-2-(ethoxymethyl)-3H-imidazo[4,5-c]quinolin-9-yl]oxy]-2-methylbutan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2)COCC)OCCC(C)(O)C REWHSGXVPGPMCX-UHFFFAOYSA-N 0.000 claims 1
- JWARRFKQCPVLSR-UHFFFAOYSA-N 4-[[4-amino-2-(ethoxymethyl)-3H-imidazo[4,5-c]quinolin-9-yl]oxy]butan-2-ol Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2)COCC)OCCC(C)O JWARRFKQCPVLSR-UHFFFAOYSA-N 0.000 claims 1
- AMPBTPQXPBRJCY-UHFFFAOYSA-N 4-amino-2-(3-methylbutyl)pyrazolo[3,4-c]quinolin-9-ol Chemical class NC1=NC=2C=CC=C(C=2C=2C1=NN(C=2)CCC(C)C)O AMPBTPQXPBRJCY-UHFFFAOYSA-N 0.000 claims 1
- PCQZTOCRIVZHOB-UHFFFAOYSA-N 4-amino-3H-pyrazolo[3,4-c]quinolin-9-ol Chemical class NC1=NC=2C=CC=C(C=2C=2C1=NNC=2)O PCQZTOCRIVZHOB-UHFFFAOYSA-N 0.000 claims 1
- FSIDHUJJSWXKCQ-UHFFFAOYSA-N 9-(3-methylbutoxy)-2-(3-methylbutyl)pyrazolo[3,4-c]quinolin-4-amine Chemical class C(CC(C)C)N1N=C2C(=NC=3C=CC=C(C=3C2=C1)OCCC(C)C)N FSIDHUJJSWXKCQ-UHFFFAOYSA-N 0.000 claims 1
- HTLWKFKYFYPSCH-UHFFFAOYSA-N 9-methoxy-3H-imidazo[4,5-c]quinolin-4-amine Chemical class COC=1C=2C3=C(C(=NC=2C=CC=1)N)N=CN3 HTLWKFKYFYPSCH-UHFFFAOYSA-N 0.000 claims 1
- ICOJRQWKSUISLK-UHFFFAOYSA-N 9-methoxy-3H-pyrazolo[3,4-c]quinolin-4-amine Chemical class COc1cccc2nc(N)c3n[nH]cc3c12 ICOJRQWKSUISLK-UHFFFAOYSA-N 0.000 claims 1
- BQICROVULNIKFQ-UHFFFAOYSA-N N-[2-[2-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxyethoxy]ethyl]methanesulfonamide Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2C)COCC)OCCOCCNS(=O)(=O)C BQICROVULNIKFQ-UHFFFAOYSA-N 0.000 claims 1
- IXGVMYREGNTOBW-UHFFFAOYSA-N N-[3-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxypropyl]acetamide Chemical class C(C)(=O)NCCCOC=1C=2C3=C(C(=NC=2C=CC=1)N)N=C(N3C)COCC IXGVMYREGNTOBW-UHFFFAOYSA-N 0.000 claims 1
- FQDKRRYLMFABOK-UHFFFAOYSA-N N-[3-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxypropyl]methanesulfonamide Chemical class CS(=O)(=O)NCCCOC=1C=2C3=C(C(=NC=2C=CC=1)N)N=C(N3C)COCC FQDKRRYLMFABOK-UHFFFAOYSA-N 0.000 claims 1
- KPRPJCGNUMXCGE-UHFFFAOYSA-N N-[3-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxypropyl]octadecanamide Chemical class C(CCCCCCCCCCCCCCCCC)(=O)NCCCOC=1C=2C3=C(C(=NC=2C=CC=1)N)N=C(N3C)COCC KPRPJCGNUMXCGE-UHFFFAOYSA-N 0.000 claims 1
- DUCMVTIPWNWNEK-UHFFFAOYSA-N N-[4-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxybutyl]acetamide Chemical class C(C)(=O)NCCCCOC=1C=2C3=C(C(=NC=2C=CC=1)N)N=C(N3C)COCC DUCMVTIPWNWNEK-UHFFFAOYSA-N 0.000 claims 1
- XSTUUKIVJMZMLY-UHFFFAOYSA-N N-[4-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxybutyl]methanesulfonamide Chemical class CS(=O)(=O)NCCCCOC=1C=2C3=C(C(=NC=2C=CC=1)N)N=C(N3C)COCC XSTUUKIVJMZMLY-UHFFFAOYSA-N 0.000 claims 1
- NDNROUSBPSFIOA-UHFFFAOYSA-N N-[4-[4-amino-2-(ethoxymethyl)-1-methylimidazo[4,5-c]quinolin-9-yl]oxybutyl]octadecanamide Chemical class NC1=NC=2C=CC=C(C=2C2=C1N=C(N2C)COCC)OCCCCNC(CCCCCCCCCCCCCCCCC)=O NDNROUSBPSFIOA-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710287322.2A CN108794467A (zh) | 2017-04-27 | 2017-04-27 | 2-氨基-喹啉衍生物 |
| CN201710287322.2 | 2017-04-27 | ||
| PCT/CN2018/084674 WO2018196823A1 (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019138177A true RU2019138177A (ru) | 2021-05-27 |
| RU2019138177A3 RU2019138177A3 (https=) | 2021-05-27 |
Family
ID=63918846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019138177A RU2019138177A (ru) | 2017-04-27 | 2018-04-26 | Производные 2-аминохинолина |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11053240B2 (https=) |
| EP (1) | EP3615539B1 (https=) |
| JP (1) | JP7179357B2 (https=) |
| KR (1) | KR102541238B1 (https=) |
| CN (3) | CN108794467A (https=) |
| AU (1) | AU2018259831B2 (https=) |
| BR (1) | BR112019022246A2 (https=) |
| CA (1) | CA3061187A1 (https=) |
| IL (1) | IL270219B (https=) |
| MX (1) | MX2019012676A (https=) |
| RU (1) | RU2019138177A (https=) |
| SG (1) | SG11201909325RA (https=) |
| WO (1) | WO2018196823A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| DK3092256T3 (da) | 2014-01-10 | 2022-06-20 | Birdie Biopharmaceuticals Inc | Forbindelser og sammensætninger til immunterapi |
| CN121243402A (zh) | 2014-07-09 | 2026-01-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1组合 |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CA3067268A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Crystalline resiquimod monosulfate anhydrate and its preparation and uses |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| BR112021016960A2 (pt) * | 2019-03-07 | 2021-11-23 | BioNTech SE | Processo para a preparação de uma imidazoquinolina substituída |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| US11339159B2 (en) * | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| CA3170551A1 (en) | 2020-03-02 | 2021-09-10 | Yong Taik Lim | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| JP7690221B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
| US20230277525A1 (en) | 2020-08-04 | 2023-09-07 | Progeneer Inc | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
| US20230346924A1 (en) | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| CA3208424A1 (en) * | 2021-02-22 | 2022-08-25 | David M. Ferguson | Immunomodulators and immunomodulator conjugates |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| MX2024000357A (es) | 2021-07-07 | 2024-02-12 | Incyte Corp | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). |
| WO2023287896A1 (en) | 2021-07-14 | 2023-01-19 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| CA3234375A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| CA3235146A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| WO2025245175A1 (en) * | 2024-05-22 | 2025-11-27 | Ajax Therapeutics, Inc. | Macrocyclic heteroaromatic inhibitors of jak2 |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US6608201B2 (en) | 1992-08-28 | 2003-08-19 | 3M Innovative Properties Company | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| BR0012196A (pt) | 1999-06-25 | 2002-03-19 | Genentech Inc | Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado |
| US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
| US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| EP1850850A4 (en) | 2000-12-08 | 2011-06-15 | 3M Innovative Properties Co | COMPOSITIONS AND METHOD FOR TARGETED ADMINISTRATION OF IMMUNE RESPONSE MODIFICATORS |
| US20030139364A1 (en) | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| EP1455700A4 (en) | 2001-11-16 | 2007-02-14 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS |
| AP2004003069A0 (en) | 2001-11-27 | 2004-06-30 | Anadys Pharmaceuticals Inc | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| EP1413316A1 (en) | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
| CA2510375A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20050036951A1 (en) | 2003-01-09 | 2005-02-17 | Arizeke Pharmaceuticals, Inc. | Methods of treating lung diseases |
| US9259459B2 (en) | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物 |
| JP2007504232A (ja) | 2003-09-05 | 2007-03-01 | アナディス ファーマシューティカルズ インク | Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与 |
| RU2426734C2 (ru) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| KR20060120069A (ko) | 2003-10-03 | 2006-11-24 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피라졸로피리딘 및 그의 유사체 |
| AR046046A1 (es) | 2003-10-03 | 2005-11-23 | 3M Innovative Properties Co | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. |
| CA2542099A1 (en) | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| US20050239735A1 (en) | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
| US8012964B2 (en) | 2004-03-26 | 2011-09-06 | Dainippon Sumitomo Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
| EP1776105A2 (en) | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
| CA2586913A1 (en) | 2004-11-09 | 2006-05-18 | University Of Southern California | Targeted innate immunity |
| PL1830876T3 (pl) | 2004-12-30 | 2015-09-30 | Meda Ab | Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi |
| CN101128431B (zh) | 2005-02-24 | 2011-05-25 | 詹森药业有限公司 | 作为钾离子通道打开剂的喹啉衍生物 |
| CN101155932A (zh) | 2005-04-14 | 2008-04-02 | 默克专利有限公司 | 基于在肿瘤组织中增加的egfr基因拷贝数的抗egfr抗体治疗 |
| JP5122441B2 (ja) | 2005-04-19 | 2013-01-16 | シアトル ジェネティックス， インコーポレイテッド | ヒト化抗ｃｄ７０結合剤およびその使用 |
| CN103285392A (zh) | 2005-04-26 | 2013-09-11 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| EP1928912A4 (en) | 2005-09-07 | 2010-02-24 | Medimmune Inc | EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS |
| ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| EP1988896A4 (en) | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | CONJUGATES TO MODIFY IMMUNE REACTIONS |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
| US8138172B2 (en) | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
| BRPI0717638A2 (pt) | 2006-10-27 | 2013-11-12 | Genentech Inc | Anticorpors e imunoconjugados e usos para os mesmos |
| MY148217A (en) | 2006-12-21 | 2013-03-29 | Hoffmann La Roche | Polymorphs of a mglur5 receptor antagonist |
| US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| CN101790380B (zh) | 2007-02-07 | 2013-07-10 | 加利福尼亚大学董事会 | 合成tlr激动剂的缀合物及其应用 |
| HRP20120895T1 (hr) | 2007-05-08 | 2012-11-30 | Astrazeneca Ab | Imidazokinolini sa imuno-modulacijskim svojstvima |
| RU2010107199A (ru) | 2007-07-31 | 2011-09-10 | Дзе Джонс Хопкинс Юниверсити (Us) | Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений |
| GB0715428D0 (en) * | 2007-08-08 | 2007-09-19 | Imp Innovations Ltd | Compositions and uses thereof |
| EP2436376B1 (en) | 2007-09-28 | 2014-07-09 | BIND Therapeutics, Inc. | Cancer cell targeting using nanoparticles |
| AU2008347400B2 (en) | 2008-01-15 | 2014-12-11 | Meda Ab | Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives |
| CA2713137C (en) | 2008-01-25 | 2017-10-24 | Hadasit Medical Research Services And Development Ltd. | Targeting of innate immune response to tumor site |
| EA201001264A1 (ru) | 2008-02-07 | 2011-04-29 | Дзе Регентс Оф Дзе Юниверсити Оф Калифорния | Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7 |
| DK2644194T3 (en) | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| EP2316032A1 (en) | 2008-08-20 | 2011-05-04 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8 |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| RS53347B (sr) | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
| EP2427485B1 (en) | 2009-05-07 | 2016-12-07 | ImmunoCellular Therapeutics, Ltd. | Cd133 epitopes |
| WO2010132622A2 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California | Anticd20-cpg conjugates and methods of treating b cell malignancies |
| US20110077263A1 (en) | 2009-09-29 | 2011-03-31 | University Of Southern California | Methods and Compositions of Toll-Like Receptor (TLR) Agonists |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011084726A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
| WO2011084725A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
| EA201690310A1 (ru) | 2010-04-13 | 2016-12-30 | Селлдекс Терапьютикс Инк. | Антитела, связывающие cd27 человека, и их применение |
| CA2798739A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| KR20130108295A (ko) | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
| EP3195868A3 (en) | 2010-10-01 | 2017-08-02 | VentiRx Pharmaceuticals, Inc. | Therapeutic use of a tlr agonist and combination therapy |
| CN103476407A (zh) | 2010-12-09 | 2013-12-25 | 霍夫曼-拉罗奇有限公司 | 用帕利他赛和曲妥珠单抗-mcc-dm1治疗her2阳性癌症 |
| DK2663555T3 (en) | 2011-01-12 | 2017-03-27 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
| WO2012104344A1 (en) | 2011-02-01 | 2012-08-09 | Genmab A/S | Human antibodies and antibody-drug conjugates against cd74 |
| TW201247706A (en) | 2011-03-08 | 2012-12-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| AU2012244549B2 (en) | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| UY34032A (es) * | 2011-04-21 | 2012-11-30 | Origenis Gmbh | Nuevos inhibidores de quinasa |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| CN103748084B (zh) | 2011-08-11 | 2016-07-06 | 亨斯迈先进材料美国有限责任公司 | 制备苯并噁嗪化合物的方法 |
| EP2758080B1 (en) | 2011-09-19 | 2018-03-07 | The Johns Hopkins University | Cancer immunotherapy |
| WO2013063277A1 (en) | 2011-10-25 | 2013-05-02 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| AU2012334825B2 (en) | 2011-11-09 | 2017-08-24 | Ascend Biopharmaceuticals Ltd | Immunomodulatory conjugates |
| WO2013166110A1 (en) | 2012-05-02 | 2013-11-07 | Yale University | Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms) |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| CN111499755A (zh) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
| TWI606063B (zh) | 2012-08-23 | 2017-11-21 | 艾澤西公司 | 結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ） |
| WO2014060113A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
| WO2014060112A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| EP2787005A1 (en) | 2013-04-02 | 2014-10-08 | Activartis Biotech GmbH | Targeted cancer immune therapy |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| DK3092256T3 (da) | 2014-01-10 | 2022-06-20 | Birdie Biopharmaceuticals Inc | Forbindelser og sammensætninger til immunterapi |
| WO2015200728A1 (en) | 2014-06-25 | 2015-12-30 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
| CN121243402A (zh) | 2014-07-09 | 2026-01-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1组合 |
| CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| JP6141568B1 (ja) | 2015-09-01 | 2017-06-07 | 大鵬薬品工業株式会社 | 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩 |
| US10821127B2 (en) | 2015-11-09 | 2020-11-03 | Shaperon Inc. | Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CA3067268A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Crystalline resiquimod monosulfate anhydrate and its preparation and uses |
| AU2019335366A1 (en) | 2018-09-07 | 2021-03-25 | Birdie Biopharmaceuticals, Inc. | Imidazoquinoline compounds and uses thereof |
| CA3125133A1 (en) | 2018-12-26 | 2020-07-02 | Birdie Biopharmaceuticals, Inc. | Immune modulatory combinations and methods for treating cancers |
| US20220175762A1 (en) | 2019-03-15 | 2022-06-09 | Birdie Biopharmaceuticals, Inc. | Immune modulatory compositions and methods for treating cancers |
| AU2021332350A1 (en) | 2020-08-26 | 2023-03-16 | Birdie Pharmaceuticals, Inc. | Cancer treatment with TLR agonist |
-
2017
- 2017-04-27 CN CN201710287322.2A patent/CN108794467A/zh active Pending
- 2017-04-27 CN CN202410623331.4A patent/CN118515666A/zh active Pending
-
2018
- 2018-04-26 CA CA3061187A patent/CA3061187A1/en active Pending
- 2018-04-26 MX MX2019012676A patent/MX2019012676A/es unknown
- 2018-04-26 EP EP18792253.9A patent/EP3615539B1/en active Active
- 2018-04-26 AU AU2018259831A patent/AU2018259831B2/en not_active Ceased
- 2018-04-26 BR BR112019022246-4A patent/BR112019022246A2/pt not_active IP Right Cessation
- 2018-04-26 KR KR1020197033158A patent/KR102541238B1/ko active Active
- 2018-04-26 WO PCT/CN2018/084674 patent/WO2018196823A1/en not_active Ceased
- 2018-04-26 US US16/608,581 patent/US11053240B2/en not_active Expired - Fee Related
- 2018-04-26 CN CN201880014574.0A patent/CN110637018B/zh active Active
- 2018-04-26 RU RU2019138177A patent/RU2019138177A/ru not_active Application Discontinuation
- 2018-04-26 SG SG11201909325R patent/SG11201909325RA/en unknown
- 2018-04-26 JP JP2019558496A patent/JP7179357B2/ja active Active
- 2018-04-26 IL IL270219A patent/IL270219B/en unknown
-
2021
- 2021-05-07 US US17/315,162 patent/US20210261549A1/en not_active Abandoned
- 2021-05-07 US US17/315,156 patent/US11834448B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3615539A4 (en) | 2020-08-19 |
| KR102541238B1 (ko) | 2023-06-08 |
| SG11201909325RA (en) | 2019-11-28 |
| CN108794467A (zh) | 2018-11-13 |
| US20210261549A1 (en) | 2021-08-26 |
| CN118515666A (zh) | 2024-08-20 |
| US20200055851A1 (en) | 2020-02-20 |
| US11834448B2 (en) | 2023-12-05 |
| KR20190141174A (ko) | 2019-12-23 |
| JP2020517711A (ja) | 2020-06-18 |
| MX2019012676A (es) | 2020-02-05 |
| US20210261548A1 (en) | 2021-08-26 |
| WO2018196823A1 (en) | 2018-11-01 |
| CN110637018A (zh) | 2019-12-31 |
| AU2018259831A1 (en) | 2019-10-31 |
| IL270219B (en) | 2022-09-01 |
| EP3615539B1 (en) | 2023-08-09 |
| EP3615539A1 (en) | 2020-03-04 |
| JP7179357B2 (ja) | 2022-11-29 |
| CA3061187A1 (en) | 2018-11-01 |
| CN110637018B (zh) | 2025-06-06 |
| BR112019022246A2 (pt) | 2020-08-11 |
| RU2019138177A3 (https=) | 2021-05-27 |
| IL270219A (https=) | 2019-12-31 |
| AU2018259831B2 (en) | 2022-06-16 |
| US11053240B2 (en) | 2021-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019138177A (ru) | Производные 2-аминохинолина | |
| JP2020517711A5 (https=) | ||
| JP2024543982A5 (https=) | ||
| ES2660831T3 (es) | Derivados de imidazol condensados útiles como inhibidores de IDO | |
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| RU2011147232A (ru) | Производное карбоновой кислоты | |
| ES2242782T3 (es) | Imidazoquinolinas sustituidas con tioeteres. | |
| RU2012138709A (ru) | Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения | |
| JP2019509276A5 (https=) | ||
| RU2018114518A (ru) | Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca) | |
| ME02124B (me) | Novi supstituisani imidazohinolini | |
| RU2013152788A (ru) | Амидные соединения и их фармацевтическое применение | |
| RU2018114289A (ru) | Бициклические соединения в качестве ингибиторов аутотаксина (atx) | |
| RU2002130252A (ru) | Замещенные амиды бензойной кислоты и их применение для подавления ангиогенеза | |
| RU2012140961A (ru) | ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ | |
| RU2015109706A (ru) | Новые производные азабензимидазол гексагидрофуро[3, 2-в]фурана | |
| RU2015120478A (ru) | Пери-карбинолы | |
| RU2013126041A (ru) | Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2 | |
| JP2016518434A5 (https=) | ||
| RU2012110246A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
| RU2018142988A (ru) | Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена | |
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| RU2015116953A (ru) | Новые соединения | |
| JP2021535213A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20220119 |